VTYX Projected Dividend Yield

Ventyx Biosciences Inc ( NASDAQ : VTYX )

Ventyx Biosciences is a clinical-stage biopharmaceutical company engaged in developing product candidates to address a range of inflammatory diseases. Co.'s primary product candidate is VTX958, an oral, selective allosteric tyrosine kinase type 2 (TYK2) inhibitor. VTX958 is designed to selectively inhibit TYK2 without detectable inhibition of other Janus kinase isoforms. In addition, Co. is developing VTX002, an oral, selective sphingosine 1 phosphate receptor 1 modulator for the treatment of ulcerative colitis. Co. is also developing a portfolio of differentiated NOD-like receptor protein 3 (NLRP3) inhibitors to address several indications driven by NLRP3 inflammasome activation.

20 YEAR PERFORMANCE RESULTS